Hunan Fangsheng Pharmaceutical Co., Ltd. - MacroPolo Hunan Fangsheng Pharmaceutical Co., Ltd. - MacroPolo
Healthcare

As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Hunan Fangsheng Pharmaceutical Co., Ltd.

Hunan Fangsheng Pharmaceutical Co., Ltd.

Company Overview

COMPANY DESCRIPTION

Fangsheng Pharmaceutical is primarily engaged in manufacturing cardiovascular and cerebrovascular, pediatric, gynecological, and anti-infective drugs. The firm began its international expansion in the United States in 2016 and is aiming for US Food and Drug Administration approval for some of its products.

CHAIRPERSON

Zhang Qinghua

HEADQUARTERS

Changsha, Hunan

PHONE

(731) 8899.7135

EMAIL

xiohanqing@fangsheng.com.cn